What's in Arcus Biosciences, Inc.'s pipeline?

Arcus Biosciences, Inc. has 8 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 6 in Phase 1.

Which companies overlap with Arcus Biosciences, Inc.'s portfolio?

Top competitors by shared drug class: Advagene Biopharma Co. Ltd., Akron Molecules AG, Allgenesis Biotherapeutics Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/arcus-biosciences-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Arcus Biosciences, Inc. — Portfolio Competitive Intelligence Brief

Arcus Biosciences, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
SG	SG	marketed	Adenosine 2A receptor antagonist	A2A receptor (adenosine 2A receptor)	Oncology

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Advagene Biopharma Co. Ltd. · 1 shared drug class
Akron Molecules AG · 1 shared drug class
Allgenesis Biotherapeutics Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Arcus Biosciences, Inc.:

Cite this brief

Drug Landscape (2026). Arcus Biosciences, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/arcus-biosciences-inc. Accessed 2026-05-16.